Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)

Key Inclusion Criteria: * Males and females ≥18 years of age * Documented GSDIa with confirmation by molecular testing * Documented history of ≥1 hypoglycemic event with blood glucose \<60 mg/dL (\<3.33 mmol/L) * Patient's GSDIa disease is stable as evidenced by no hospitalization for severe hypoglycemia during the 4-week period preceding the screening visit Key Exclusion Criteria: * Anti-AAV8 neutralizing antibody titer ≥1:5 * Screening or Baseline (Day 0) blood glucose level \<60 mg/dL (\<3.33 mmol/L) * Liver transplant, including hepatocyte cell therapy/transplant * Presence of liver adenoma \>5 cm in size * Presence of liver adenoma \>3 cm and ≤5 cm in size that has a documented annual growth rate of ≥0.5 cm per year * Significant hepatic inflammation or cirrhosis as evidenced by imaging or any of the following laboratory abnormalities: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> upper limit of normal (ULN), total bilirubin \> 1.5 x ULN, or alkaline phosphatase \> 2.5 x ULN Note additional inclusion/exclusion criteria may apply, per protocol.